Effect of β-alanine Supplementation on Muscle Carnosine (LitmusMagnet)

This study has been completed.
Sponsor:
Collaborators:
University of Bern
University Hospital Inselspital, Berne
Information provided by (Responsible Party):
Nestlé
ClinicalTrials.gov Identifier:
NCT00813553
First received: December 22, 2008
Last updated: April 24, 2012
Last verified: April 2012
  Purpose

Carnosine is a natural acid buffering substance of muscle. The primary objective of this study is to test whether a nutritional supplement of beta-alanine enhances carnosine content in muscle.


Condition Intervention
Healthy
Dietary Supplement: placebo
Dietary Supplement: beta-alanine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine

Resource links provided by NLM:


Further study details as provided by Nestlé:

Primary Outcome Measures:
  • muscle carnosine concentration [ Time Frame: 0 to 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: December 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: beta-alanine 0 Dietary Supplement: placebo
daily
Experimental: beta-alanine 1 Dietary Supplement: beta-alanine
daily
Experimental: beta-alanine 2 Dietary Supplement: beta-alanine
daily

Detailed Description:

Volunteers will be randomized to receiving 3 nutritional supplements. Two supplements contain beta-alanine at different doses, the third supplement is a placebo.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Stable health as evaluated by medical evaluation
  • Body mass index higher than 18 kg/m2
  • Body mass index lower than 25 kg/m2, unless body fat is less than 20%

Exclusion Criteria:

  • intolerance to β-alanine,
  • allergy to soy, fish and crustacean
  • participation in another intervention study
  • consumer of dietary supplement susceptible to contain beta-alanine
  • determined to have very high baseline muscle carnosine concentration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00813553

Locations
Switzerland
University and Inselspital
Bern, Switzerland, 3010
Sponsors and Collaborators
Nestlé
University of Bern
University Hospital Inselspital, Berne
  More Information

No publications provided

Responsible Party: Nestlé
ClinicalTrials.gov Identifier: NCT00813553     History of Changes
Other Study ID Numbers: 08.13.PER
Study First Received: December 22, 2008
Last Updated: April 24, 2012
Health Authority: Switzerland: Ethikkommission

Keywords provided by Nestlé:
physical fitness
exercise
amino acid

ClinicalTrials.gov processed this record on July 23, 2014